Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient ... Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts. Mehr anzeigen
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York...
In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today...
Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity...
Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program Separate studies with patients on GLP-1 therapy report significant weight...
Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York...
Results highlighted by strong sequential revenue growth and record procedure volume Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity...
Allurion Technologies, Inc. (NYSE: ALUR), une entreprise qui s’est donné pour objectif de combattre l’obésité, a annoncé aujourd'hui avoir suspendu les ventes du Ballon Allurion en France à la...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.085 | -12.5 | 0.68 | 0.8898 | 0.5601 | 728018 | 0.60166335 | CS |
| 4 | -0.175 | -22.7272727273 | 0.77 | 0.89005 | 0.5601 | 274688 | 0.62951997 | CS |
| 12 | -0.835 | -58.3916083916 | 1.43 | 3.55 | 0.5601 | 1484403 | 2.27476128 | CS |
| 26 | -2.165 | -78.4420289855 | 2.76 | 3.95 | 0.5601 | 1196701 | 2.58813287 | CS |
| 52 | -4.075 | -87.2591006424 | 4.67 | 6.43 | 0.5601 | 627483 | 2.69123907 | CS |
| 156 | -8.405 | -93.3888888889 | 9 | 9 | 0.5601 | 578046 | 2.72665699 | CS |
| 260 | -8.405 | -93.3888888889 | 9 | 9 | 0.5601 | 578046 | 2.72665699 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
